Recent publications

Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology

Lauren, Ida; Havervall, Sebastian; Ng, Henry; Lord, Martin et al.

Part of Immunity, Inflammation and Disease, 2022.

DOI for Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology Download full text (pdf) of Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology

Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines

Marking, Ulrika; Havervall, Sebastian; Greilert-Norin, Nina; Ng, Henry et al.

Part of Vaccines, 2022.

DOI for Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines Download full text (pdf) of Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines

Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials

Ellingsen, Espen Basmo; Aamdal, Elin; Guren, Tormod; Lilleby, Wolfgang et al.

Part of Journal for ImmunoTherapy of Cancer, 2022.

DOI for Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials Download full text (pdf) of Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials

Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19

Havervall, Sebastian; Ng, Henry; Jernbom Falk, August; Greilert-Norin, Nina et al.

Part of Journal of Internal Medicine, p. 72-80, 2022.

DOI for Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19 Download full text (pdf) of Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19

Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection

Blom, Kim; Marking, Ulrika; Havervall, Sebastian; Norin, Nina Greilert et al.

Part of Lancet. Infectious diseases (Print), p. 943-945, 2022.

DOI for Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection

Factors Associated With Serological Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Rituximab

Tolf, Andreas; Wiberg, Anna; Müller, Malin; Nazir, Faisal Hayat et al.

Part of JAMA Network Open, 2022.

DOI for Factors Associated With Serological Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Rituximab Download full text (pdf) of Factors Associated With Serological Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Rituximab

An Adaptable Antibody-Based Platform for Flexible Synthetic Peptide Delivery Built on Agonistic CD40 Antibodies

Eltahir, Mohamed; Lauren, Ida; Lord, Martin; Chourlia, Aikaterini et al.

Part of Advanced Therapeutics, 2022.

DOI for An Adaptable Antibody-Based Platform for Flexible Synthetic Peptide Delivery Built on Agonistic CD40 Antibodies Download full text (pdf) of An Adaptable Antibody-Based Platform for Flexible Synthetic Peptide Delivery Built on Agonistic CD40 Antibodies

Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination

Ellingsen, Espen Basmo; Bounova, Gergana; Kerzeli, Iliana Kyriaki; Anzar, Irantzu et al.

Part of Journal of Translational Medicine, 2022.

DOI for Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination Download full text (pdf) of Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination

Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time

Havervall, Sebastian; Marking, Ulrika; Greilert-Norin, Nina; Gordon, Max et al.

Part of Clinical & Translational Immunology (CTI), 2022.

DOI for Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time Download full text (pdf) of Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time

SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection

Havervall, Sebastian; Falk, August Jernbom; Klingstrom, Jonas; Ng, Henry et al.

Part of PLOS ONE, 2022.

DOI for SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection Download full text (pdf) of SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection

Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients

Eltahir, mohmo394; Fletcher, E.; Dynesius, L.; Jarblad, J. L. et al.

Part of International Immunopharmacology, 2021.

DOI for Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients Download full text (pdf) of Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients

Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers

Havervall, Sebastian; Rosell, Axel; Phillipson, Mia; Mangsbo, Sara et al.

Part of Journal of the American Medical Association (JAMA), p. 2015-2016, 2021.

DOI for Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers

Fed-batch production assessment of a tetravalent bispecific antibody: A case study on piggyBac stably transfected HEK293 cells

Napoleone, Antonino; Laurén, Ida; Linkgreim, Triinu; Dahllund, Leif et al.

Part of New Biotechnology, p. 9-19, 2021.

DOI for Fed-batch production assessment of a tetravalent bispecific antibody: A case study on piggyBac stably transfected HEK293 cells Download full text (pdf) of Fed-batch production assessment of a tetravalent bispecific antibody: A case study on piggyBac stably transfected HEK293 cells

Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2

Havervall, Sebastian; Marking, Ulrika; Greilert-Norin, Nina; Ng, Henry et al.

Part of EBioMedicine, 2021.

DOI for Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2 Download full text (pdf) of Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2

Single-cell RNAseq and longitudinal proteomic analysis of a novel semi-spontaneous urothelial cancer model reveals tumor cell heterogeneity and pretumoral urine protein alterations

Kerzeli, Iliana Kyriaki; Lord, Martin; Doroszko, Milena; Elgendy, Ramy et al.

Part of PLOS ONE, 2021.

DOI for Single-cell RNAseq and longitudinal proteomic analysis of a novel semi-spontaneous urothelial cancer model reveals tumor cell heterogeneity and pretumoral urine protein alterations Download full text (pdf) of Single-cell RNAseq and longitudinal proteomic analysis of a novel semi-spontaneous urothelial cancer model reveals tumor cell heterogeneity and pretumoral urine protein alterations

An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses

Mangsbo, Sara; Havervall, Sebastian; Laurén, Ida; Lindsay, Robin et al.

Part of PLOS ONE, 2021.

DOI for An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses Download full text (pdf) of An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses

Infiltration of NK and plasma cells is associated with a distinct immune subset in non‐small cell lung cancer

Backman, Max; La Fleur, Linnea; Kurppa, Pinja; Djureinovic, Dijana et al.

Part of Journal of Pathology, p. 243-256, 2021.

DOI for Infiltration of NK and plasma cells is associated with a distinct immune subset in non‐small cell lung cancer Download full text (pdf) of Infiltration of NK and plasma cells is associated with a distinct immune subset in non‐small cell lung cancer

Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade

Eltahir, Mohamed; Isaksson, Johan; Mattsson, Johanna Sofia Margareta; Karre, Klas et al.

Part of Cancers, 2021.

DOI for Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade Download full text (pdf) of Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade

Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma

van Hooren, Luuk; Vaccaro, Alessandra; Ramachandran, Mohanraj; Vazaios, Konstantinos et al.

Part of Nature Communications, 2021.

DOI for Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma Download full text (pdf) of Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma

Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy

Georganaki, Maria; Ramachandran, Mohanraj; Tuit, Sander; Nunez, Nicolas Gonzalo et al.

Part of Oncoimmunology, 2020.

DOI for Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy Download full text (pdf) of Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy

Flodvåg av långtidssjuka covid-19-patienter väntar

Rostedt Punga, Anna; Strömme, Maria; Alimohammadi, Mohammed; Eltahir, Mohammed et al.

Part of Dagens Nyheter, p. 5-5, 2020.

Tumor localized agonistic anti-CD40 therapy and beyond

Eltahir, Mohamed; Persson, Helena; Mangsbo, Sara

Part of Expert Opinion on Biological Therapy, p. 215-217, 2020.

DOI for Tumor localized agonistic anti-CD40 therapy and beyond

Reactive oxygen species as an initiator of toxic innate immune responses in retort to SARS-CoV-2 in an ageing population, consider N-acetylcysteine as early therapeutic intervention

Nasi, Aikaterini; McArdle, Stephanie; Gaudernack, Gustav; Westman, Gabriel et al.

Part of Toxicology reports, p. 768-771, 2020.

DOI for Reactive oxygen species as an initiator of toxic innate immune responses in retort to SARS-CoV-2 in an ageing population, consider N-acetylcysteine as early therapeutic intervention Download full text (pdf) of Reactive oxygen species as an initiator of toxic innate immune responses in retort to SARS-CoV-2 in an ageing population, consider N-acetylcysteine as early therapeutic intervention

BCG-induced cytokine release in bladder cancer cells is regulated by Ca2+ signaling

Ibarra, Cristian; Karlsson, Marie; Codeluppi, Simone; Varas-Godoy, Manuel et al.

Part of Molecular Oncology, p. 202-211, 2019.

DOI for BCG-induced cytokine release in bladder cancer cells is regulated by Ca2+ signaling Download full text (pdf) of BCG-induced cytokine release in bladder cancer cells is regulated by Ca2+ signaling

Linking T cell epitopes to a common linear B cell epitope: A targeting and adjuvant strategy to improve T cell responses

Mangsbo, Sara; Fletcher, Erika; van Maren, Wendy; Redeker, Anke et al.

Part of Molecular Immunology, p. 115-124, 2018.

DOI for Linking T cell epitopes to a common linear B cell epitope: A targeting and adjuvant strategy to improve T cell responses

Formation of Immune Complexes with a Tetanus-Derived B Cell Epitope Boosts Human T Cell Responses to Covalently Linked Peptides in an Ex Vivo Blood Loop System

Fletcher, Erika; van Maren, Wendy; Cordfunke, Robert; Dinkelaar, Jasper et al.

Part of Journal of Immunology, p. 87-97, 2018.

DOI for Formation of Immune Complexes with a Tetanus-Derived B Cell Epitope Boosts Human T Cell Responses to Covalently Linked Peptides in an Ex Vivo Blood Loop System

Extracorporeal human whole blood in motion, as a tool to predict first-infusion reactions and mechanism-of-action of immunotherapeutics

Fletcher, Erika A. K.; Eltahir, Mohamed; Lindqvist, Frida; Rieth, Jonas et al.

Part of International Immunopharmacology, p. 1-11, 2018.

DOI for Extracorporeal human whole blood in motion, as a tool to predict first-infusion reactions and mechanism-of-action of immunotherapeutics Download full text (pdf) of Extracorporeal human whole blood in motion, as a tool to predict first-infusion reactions and mechanism-of-action of immunotherapeutics

Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment

Eriksson, Emma; Moreno, R; Milenova, I. Yoanna; Liljenfeldt, L et al.

Part of Gene Therapy, p. 92-103, 2017.

DOI for Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment Download full text (pdf) of Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment

Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients

Schiza, Aglaia; Wenthe, Jessica; Mangsbo, Sara; Svensson, Emma et al.

Part of Journal of Translational Medicine, 2017.

DOI for Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients Download full text (pdf) of Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients

Adenovirus-mediated CD40L gene transfer increases teffector/tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients

Schiza, Aglaia; Wenthe, Jessica; Mangsbo, Sara; Eriksson, Emma et al.

Part of Scandinavian Journal of Immunology, p. 337-337, 2017.

Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer

van Hooren, Luuk; Sandin, Linda C.; Moskalev, Igor; Ellmark, Peter et al.

Part of European Journal of Immunology, p. 385-393, 2017.

DOI for Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer

Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients

Irenaeus, Sandra; Schiza, Aglaia; Mangsbo, Sara M.; Wenthe, Jessica et al.

Part of OncoTarget, p. 78573-78587, 2017.

DOI for Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients Download full text (pdf) of Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients

Selective Fc gamma R engagement by human agonistic anti-CD40 antibodies

Ellmark, Peter; Mangsbo, Sara M.; Lindstedt, Malin

Part of Translational Cancer Research, p. S839-S841, 2016.

DOI for Selective Fc gamma R engagement by human agonistic anti-CD40 antibodies

Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment

van Hooren, Luuk; Georganaki, Maria; Huang, Hua; Mangsbo, Sara M. et al.

Part of OncoTarget, p. 50277-50289, 2016.

DOI for Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment Download full text (pdf) of Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment

Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients

Loskog, Angelica; Maleka, Aglaia; Mangsbo, Sara; Svensson, Emma et al.

Part of British Journal of Cancer, p. 872-880, 2016.

DOI for Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients

The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T cell dependent tumor immunity

Mangsbo, Sara M; Broos, Sissela; Fletcher, Erika; Veitonmäki, Niina et al.

Part of Clinical Cancer Research, p. 1115-1126, 2015.

DOI for The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T cell dependent tumor immunity

The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses

Christiansson, Lisa; Söderlund, Stina; Mangsbo, Sara; Hjorth-Hansen, Henrik et al.

Part of Molecular Cancer Therapeutics, p. 1181-1191, 2015.

DOI for The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses

Kick-starting the cancer-immunity cycle by targeting CD40

Ellmark, P.; Mangsbo, Sara M.; Furebring, C.; Tötterman, Thomas H. et al.

Part of Oncoimmunology, 2015.

DOI for Kick-starting the cancer-immunity cycle by targeting CD40

Antibody induced CD4 down-modulation of T cells is site-specifically mediated by CD64(+) cells

Vogel, Stephanie; Grabski, Elena; Buschjaeger, Daniela; Klawonn, Frank et al.

Part of Scientific Reports, 2015.

DOI for Antibody induced CD4 down-modulation of T cells is site-specifically mediated by CD64(+) cells Download full text (pdf) of Antibody induced CD4 down-modulation of T cells is site-specifically mediated by CD64(+) cells

CD40L gene therapy tilts the myeloid cell profile and promotes infiltration of activated T lymphocytes

Liljenfeldt, Lina; Dieterich, Lothar C.; Dimberg, Anna; Mangsbo, Sara M. et al.

Part of Cancer Gene Therapy, p. 95-102, 2014.

DOI for CD40L gene therapy tilts the myeloid cell profile and promotes infiltration of activated T lymphocytes

The cerebrospinal fluid cytokine signature of multiple sclerosis: A homogenous response that does not conform to the Th1/Th2/Th17 convention

Burman, Joachim; Svensson, Emma; Fransson, Moa; Loskog, Angelica S I et al.

Part of Journal of Neuroimmunology, p. 153-159, 2014.

DOI for The cerebrospinal fluid cytokine signature of multiple sclerosis: A homogenous response that does not conform to the Th1/Th2/Th17 convention

Tim-3 and PD-1: Regulators of adaptive immunity in multiple sclerosis

Burman, Joachim; Svensson, Emma; Fransson, Moa; Loskog, Angelica et al.

Part of Journal of Neuroimmunology, p. 141-141, 2014.

DOI for Tim-3 and PD-1: Regulators of adaptive immunity in multiple sclerosis

FcγRIIb on myeloid cells rather than on B cells protects from collagen-induced arthritis

Yilmaz-Elis, A Seda; Ramirez, Javier Martin; Asmawidjaja, Patrick; van der Kaa, Jos et al.

Part of Journal of Immunology, p. 5540-5547, 2014.

DOI for FcγRIIb on myeloid cells rather than on B cells protects from collagen-induced arthritis

Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer

Sandin, Linda; Orlova, Anna; Gustafsson, Erika; Ellmark, Peter et al.

Part of Cancer Immunology Research, p. 80-90, 2014.

DOI for Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer Download full text (pdf) of Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer

AdCD40L Immunostimulatory Gene Therapy in Combination with Cyclophosphamide Prolongs 6-Months Survival in a Phase I/II Trial for Malignant Melanoma

Loskog, Angelica; Maleka, Aglaia; Mangsbo, Sara; Svensson, Emma et al.

Part of Molecular Therapy, p. S247-S247, 2014.

The use of multiplex platforms for absolute and relative protein quantification of clinical material

Christiansson, Lisa; Mustjoki, Satu; Simonsson, Bengt; Olsson-Strömberg, Ulla et al.

Part of EuPA Open Proteomics, p. 37-47, 2014.

DOI for The use of multiplex platforms for absolute and relative protein quantification of clinical material

Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo

Sandin, Linda C.; Eriksson, Fredrik; Ellmark, Peter; Loskog, Angelica S. I. et al.

Part of Oncoimmunology, p. e2761-, 2014.

DOI for Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo

Local immunotherapy based on agonistic CD40 antibodies effectively inhibits experimental bladder cancer

Sandin, Linda C.; Tötterman, Thomas H.; Mangsbo, Sara M.

Part of Oncoimmunology, 2014.

DOI for Local immunotherapy based on agonistic CD40 antibodies effectively inhibits experimental bladder cancer

A Hexon and Fiber-modified Adenovirus Expressing CD40L Improves the Antigen Presentation Capacity of Dendritic Cells

Liljenfeldt, Lina; Yu, Di; Chen, Liye; Essand, Magnus et al.

Part of Journal of immunotherapy (1997), p. 155-162, 2014.

DOI for A Hexon and Fiber-modified Adenovirus Expressing CD40L Improves the Antigen Presentation Capacity of Dendritic Cells

AdCD40L immunostimulatory gene therapy shifts the MDSC- and macrophage profiles and promotes T cell infiltration in the tumor microenvironment

Liljenfeldt, Lina; Svensson, E.; Huang, H.; Dieterich, L. et al.

Part of Human Gene Therapy, p. A169-A169, 2013.